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Abstract
Aims Inpatient hypoglycaemia is common and associated
with adverse outcomes. There is often increased vigilance
of hypoglycaemia in inpatients with type 1 diabetes
(T1DM) compared to type 2 diabetes (T2DM). We aimed
to investigate this apparent discrepancy, utilising the time
to repeat (TTR) capillary blood glucose (CBG) measure-
ment as a surrogate for engagement with guidelines stating
that CBG should be rechecked following intervention
within 15 min of an initial CBG of\4 mmol/L.
Methods This is an observational study of inpatient CBG
data from 8 hospitals over a 7-year period. A national
diabetes registry allowed identification of individual’s
diagnosis and diabetes therapy. For each initial (index)
CBG, the TTR for individuals with T2DM—on insulin or
sulphonylurea—was compared with the TTR for individ-
uals with T1DM, using a t test for significance performed
on log(TTR). The median TTR was plotted for each group
per index CBG.
Results In total, 1480,335 CBG measurements were
obtained. A total of 26,664 were\4 mmol/L. The TTR in
T2DM individuals on sulphonylurea was significantly
greater than in T1DM individuals where index CBG was
C2.3 mmol/L (except index CBG 2.6 mmol/L). For T2DM
patients receiving insulin significance exists for index
CBGs of C3.2 mmol/L.
Conclusions This analysis suggests that quality of care of
hypoglycaemia varies according to diagnosis and medica-
tion. The group with the highest TTR (T2DM sulphony-
lurea treated) are possibly the clinical group in whom
hypoglycaemia is most concerning. These data therefore
suggest a need for education and raising awareness within
the inpatient nursing staff.
Keywords Diabetes  Inpatient  Hypoglycaemia  Insulin 
Sulphonylurea  Quality of care
Background and aims
Hypoglycaemia is an important co-morbidity in most
patients with type 1 diabetes and many with type 2 diabetes
and has potentially fatal consequences [1]. Fewer than 20%
of patients with type 1 diabetes (T1DM) are free of
hypoglycaemia in any year [2]. In patients with type 2
diabetes (T2DM), it has been reported that by 9 months of
follow-up 7% of patients on recently initiated insulin or
sulphonylurea treatment will have experienced severe
hypoglycaemia (hypoglycaemia needing external assis-
tance) [3]. Occurrence of severe hypoglycaemia has
demonstrated to be associated with macrovascular events,
adverse clinical outcomes and mortality in people with
T1DM and T2DM [4, 5]. As well as poor clinical outcomes
hypoglycaemia is a complication greatly feared by patients
and associated with significant psychological and social
burdens [6, 7].
In hospitalised patients with diabetes, hypoglycaemia is
common with a reported frequency of between 3.3 and
5.7% [8–11]. In the UK National Diabetes Inpatient Audit,
hypoglycaemia occurred in 45.3% of inpatients with
T1DM and 31.8% T2DM [12].
Managed by Antonio Secchi.
& Gregory C. Jones
g.jones3@nhs.net
1 Diabetes Department, Gartnavel General Hospital,
Glasgow G11 0YN, UK
123
Acta Diabetol
DOI 10.1007/s00592-016-0940-3
Sulphonylureas (SUs) pose a significant hypoglycaemic
risk with a reported incidence of 19% of inpatients treated
with SUs [13] and one-third of hypoglycaemic episodes
attributed exclusively to SU therapy in an audit of 11 acute
UK NHS trusts [14]. Although severity of hypoglycaemia
was significantly greater with insulin therapy, the number
of episodes of hypoglycaemia experienced was similar
[13, 14].
Frequency and severity of hypoglycaemia have been
associated with an increase in pre- and postdischarge
mortality and length of admission [15–17]. Even in patients
without diabetes, hypoglycaemia on hospital admission has
been linked with a significant increase in inpatient mor-
tality and bed occupancy [18, 19].
Patients experiencing hypoglycaemia (blood glu-
cose\ 4 mmol/l) require prompt action with administra-
tion of rapid acting carbohydrate or glucagon followed by
assessment of response to treatment by repeat blood glu-
cose measurement. The Joint British Diabetes Societies
inpatient care guidelines for the treatment of hypogly-
caemia recommend that following treatment of hypogly-
caemia capillary blood glucose (CBG) is repeated at
between 10 and 15 min to ensure successful treatment [12].
This timescale for repeating CBG is also recommended by
the American Diabetes Association for all episodes of
hypoglycaemia occurring in patients with diabetes [20].
Compliance with guidelines for repeat testing following
identification of hypoglycaemia is substandard. In a 5-year
analysis of 8 acute hospitals in the UK, it was revealed that
following recorded hypoglycaemia events 4.4% of patients
had no repeat CBG. Of the repeated measurements, less
than 10% had a TTR\ 15 min and the median TTR was
80 min. As would seem instinctive, a proportional rela-
tionship was seen with TTR and severity of initial CBG
values [21].
It has been our experience that in an inpatient setting
there is often a high degree of awareness of hypoglycaemia
in individuals with T1DM, but less awareness for those
with T2DM.
We aimed to investigate for both the presence and scale
of this apparent discrepancy in clinical vigilance by util-
ising the time to repeat (TTR) capillary blood glucose
(CBG) measurement as a surrogate for engagement with
extant clinical guidelines for hypoglycaemia—which in our
institution state that CBG should be rechecked following
intervention within 15 min where an initial CBG of
\4 mmol/L is identified.
Patients and methods
Inpatient CBG data were collected from 8 hospitals,
comprising a variety of acute and general medical and
surgical wards in district general and teaching hospitals, in
the Greater Glasgow and Clyde Health Board over a period
of 7 years to January 2016. CBG value, time of test, date of
test and corresponding patient identifier were extracted
from analysis of the Abbott Precision Webb system (Ab-
bott, UK). Episodes of hypoglycaemia were identified as
CBG of \4 mmol/l. Repeat CBG testing for the same
patient identifier was then identified, and the time between
the test was calculated to give the TTR. By merging the
dataset with a national diabetes registry (Scottish Care
Information Diabetes Collaboration System), it was possi-
ble to cross-reference patient identifiers and identify the
individual’s diagnosis of T1DM or T2DM.
Primary care prescribing information was available from
the registry for all individuals with diabetes. Admissions
were deemed to be associated with insulin or SU therapies if
a prescription was identified during the 4 months prior to
admission. During an admission, the time interval between
each CBG measurement was calculated and analysed per
initial (index) CBG value. For each index CBG, the TTR for
those individuals with T2DM—insulin or SU treated—was
compared with the TTR for those individuals with T1DM,
using a t test performed on log(TTR) to test significance. The
median TTR was plotted for each group per index CBG.
Results
A summary of results is represented in Table 1. In total,
1,480,335 CBG measurements were obtained by the Abbott
system in total. This comprised 406,690 values from 4304
individuals with T1DM, 484,067 values from 5164 indi-
viduals with T2DM on insulin therapy and 589,778 values
from 13,015 individuals with T2DM on sulphonylureas
(SU).
Table 1 Summary of diagnosis, therapy, number of CBG values and median TTR (IQR)
Diagnosis and
therapy
Number of
individuals
Number of CBG
values
CBG values
\4 mmol/l
Median (IQR) TTR
overall (min)
Median (IQR) TTR for CBG
1–3.9 mmol/l (min)
T1DM 4304 406,690 26,664 186 (90–314) 53 (26–112)
T2DM ? Insulin 5164 484,067 23,591 305 (159–552) 64 (30–147)
T2DM ? SU 13,015 589,778 30,344 355 (198–706) 97 (40–292)
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Of these readings, 26,664 were identified as being
hypoglycaemic (\4 mmol/L) from individuals with
T1DM, 23,591 from individuals with T2DM on insulin and
30,344 from individuals with T2DM on sulphonylurea
therapy.
The overall median (IQR) TTR for all index CBG
values (1–27.8 mmol/l) was: 186 (90–314) min in indi-
viduals with T1DM; 305 (159–552) min in patients with
T2DM on insulin; and 355 (198–706) min in T2DM
patients on SU.
The median (IQR) TTR for index CBGs in the range of
1–3.9 mmol/L was: 53 (26–112) min in individuals with
T1DM; 64 (30–147) min in patients with T2DM on insulin;
and 97 (40–292) min in T2DM patients on SU.
Figure 1 shows the relationship between the median
TTR of CBG compared to index CBG level in patients with
T1DM, T2DM treated with insulin and T2DM treated with
a sulphonylurea with an indicator of significance where
each T2DM group is compared with the T1DM group. The
TTR in the subgroup of T2DM individuals on SU therapy
is significantly greater than in T1DM individuals where the
index CBG is C2.3 mmol/L (except index CBG 2.6 mmol/
L). For the portion of T2DM patients receiving insulin
significance exists for index CBGs of C3.2 mmol/L.
Conclusion
As has been reported previously the nationally agreed
standard of repeating CBG following measured hypogly-
caemia is not being met in the vast majority of patients
[21]. Guidelines suggest identical action for hypogly-
caemic CBGs regardless of clinical context. This analysis
suggests that the level of adherence to guidance (which is a
measure of quality of care) varies according to the
underlying diagnosis and prescribed drugs. TTR decreases
as the index CBG decreases as clinically expected, and a
reduction in TTR is seen at those thresholds where the
initial number of the CBG result decreases (e.g. 3.0 vs.
2.9)—as previously reported.
The difference in attitude towards noninsulin therapies
was highlighted by the TOPDOC study. Investigation of
confidence and approaches to delivery of diabetes care
found that postgraduate medical trainees were less likely to
alter oral therapy for diabetes management compared to
insulin [22].
Rates of hypoglycaemia in T2DM patients on insulin are
lower than for T1DM patients, although disparity reduces
with advancement of disease [23]. Irrespective of cause
hypoglycaemia is associated with a multitude of negative
outcomes, and recent publications have identified comor-
bidity as potentially the most concerning contributor to
hypoglycaemia [24], [25]. Patients admitted to hospital are
likely to suffer from more advanced disease and comor-
bidities. They are also more likely to suffer from the risk
factors associated with SU-induced hypoglycaemia,
namely older age and reduced kidney function [13]. Fur-
thermore, hypoglycaemia and SU therapy have both been
implicated in direct cardiotoxicity, although causative
evidence in this area is lacking [26].
Thus, although, understandably, there may be increased
vigilance of hypoglycaemia in T1DM patients, the group
with the highest TTR (T2DM SU treated) are possibly the
clinical group in whom the risks associated with hypo-
glycaemia are greatest.
These data therefore suggest a need for education and
raising awareness within the nursing staff within inpatient
units. The benefit of such intervention in improving quality
of inpatient hypoglycaemia care has been evidenced pre-
viously [21].
Fig. 1 Median time to repeat of
CBG by index CBG in mmol/l
for T1DM (green), insulin-
treated T2DM (black) and
sulphonylurea-treated T2DM
(purple) (colour figure online)
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